Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer
International Journal of Molecular Sciences · 20.05.2023 · 24 (10) · 9038
DOI: 10.3390/ijms24109038 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.05.2023. Verfasst von Martin J Raftery und 7 weiteren Autor:innen. Beteiligte Einrichtung: Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SPARK-program of the Berlin Institute of Health@Charite, Berlin Institute of Health at Charité.
Abstract (Originalsprache)
There is a medical need to develop new and effective therapies against triple-negative breast cancer (TNBC). Chimeric antigen receptor (CAR) natural killer (NK) cells are a promising alternative to CAR-T cell therapy for cancer. A search for a suitable target in TNBC identified CD44v6, an adhesion molecule expressed in lymphomas, leukemias and solid tumors that is implicated in tumorigenesis and metastases. We have developed a next-generation CAR targeting CD44v6 that incorporates IL-15 superagonist and checkpoint inhibitor molecules. We could show that CD44v6 CAR-NK cells demonstrated effective cytotoxicity against TNBC in 3D spheroid models. The IL-15 superagonist was specifically released upon recognition of CD44v6 on TNBC and contributed to the cytotoxic attack. PD1 ligands are upregulated in TNBC and contribute to the immunosuppressive tumor microenvironment (TME). Competitive inhibition of PD1 neutralized inhibition by PD1 ligands expressed on TNBC. In total, CD44v6 CAR-NK cells are resistant to TME immunosuppression and offer a new therapeutic option for the treatment of BC, including TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
- Onkologie und Tumorimmunologie, CCM, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Charitéplatz 1, 10117 Be…
- Institute of Virology, CCM, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.
- Department of Gynecology and Breast Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.
ORCID-Profile: Alexander Sebastian Franzén, Günther Schönrich, Sebastian Stintzing, Jens-Uwe Blohmer
Förderung
- SPARK-program of the Berlin Institute of Health@Charite
- Berlin Institute of Health at Charité
Zitieren
APA
Raftery, M. J., Franzén, A. S., Radecke, C., Boulifa, A., Schönrich, G., Stintzing, S., Blohmer, J. U., & Pecher, G. (2023). Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer. International Journal of Molecular Sciences, 24(10), 9038. https://doi.org/10.3390/ijms24109038
Vancouver
Raftery MJ, Franzén AS, Radecke C, Boulifa A, Schönrich G, Stintzing S, et al. Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer. International Journal of Molecular Sciences. 2023;24(10):9038. doi:10.3390/ijms24109038
BibTeX
@article{Raftery2023,
author = {Raftery, Martin J and Franzén, Alexander Sebastian and Radecke, Clarissa and Boulifa, Abdelhadi and Schönrich, Günther and Stintzing, Sebastian and Blohmer, Jens-Uwe and Pecher, Gabriele},
title = {Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {10},
pages = {9038},
doi = {10.3390/ijms24109038}
}
EUVIMED